Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Coherus_Bio
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Coherus_Bio
-
.
@USBiosimilars President Juliana Reed: “Despite the tough political climate, Congress has rightfully recognized that increasing access to biosimilars is a necessary part of the solution to America’s rising health care costs.”https://bit.ly/38P0EIzHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our President, CEO & Chairman, Denny Lanfear, on recent efforts from the
@FDA_Drug_Info and@FTC to deter anti-competitive practices in the biologics market.pic.twitter.com/JZhX6T8hxU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A panel at the Specialty Therapies and Biosimilars Congress discussed the keys to a successful
#biosimilar launch. Developing a long-range marketing strategy to build trust was one of the takeaways shared by the participants. More here:http://bit.ly/36ENNaaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"At some point, you simply have an event which causes a tectonic shift in thinking,” said Denny Lanfear,
@Coherus_Bio President & CEO, on the rising cost of healthcare. Coherus drives down drug costs through#biosimilar market competition. More here:https://bloom.bg/2OezF1hHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
As of December 2019, the
@US_FDA has approved 27#biosimilars, and 12 are currently on the market. Learn more about the rigorous approval process and why experts believe there will be a large uptake of biosimilars in upcoming years:https://bit.ly/2vj99gzHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"These strong approval figures demonstrate biopharmaceutical companies' unwavering commitment to developing innovative treatments for patients," says
@AndrewPowaleny from@PhRMA, while discussing the innovative medicines approved in 2019.https://onphr.ma/2NU6bFPHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With an average cost of 26% less than their reference products,
#biosimilars could provide up to $150B in savings over the next decade, notes @USBiosimilar President Juliana Reed in a recent op-ed. Read more: http://bit.ly/2srsY46 pic.twitter.com/aJvALWgvrO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Biosimilars have struggled to gain traction in the U.S. despite widespread adoption in Europe. Experts take recent successful launches as a positive sign for the biosimilar market overall in 2020. More:http://bit.ly/38qapfTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Chip Davis, President & CEO of
@AccessibleMeds sees "fearmongering about the quality of biosimilars" perception and lobbying efforts as reasons for slow uptake in the U.S. By enacting incentives for#biosimilars, usage will increase.http://bit.ly/30R80IVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Watch: Gillian Woollett, MA, DPhil, Senior Vice President at Avalere Health, discuss recommended changes for the development and approval process of#biosimilars.https://youtu.be/m3Su76LnHvYHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Patent reform can help
#biosimilars compete and deliver savings to the healthcare system. Matthew Lane, Executive Director of the@capanow1, argues these reforms should be a bipartisan issue. More here:http://bit.ly/3aArFBlHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#biosimilars market is expected to expand in the coming years as many reference drugs will soon lose patent exclusivity. By 2026,#biosimilars could save as much as $150 billion according to a recent article in@FiercePharma. More: http://bit.ly/2NoL12k pic.twitter.com/DOEZ0yQLUQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ICYMI:@OubreKathy, COO of Pontchartrain Cancer Center: "The availability of#biosimilars introduces competition based on price, offering a lower-cost alternative in the short term and helping to restrict—or even reverse—longer-term price growth."https://bit.ly/2s8JZjnHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#2020 is an exciting year for
#biosimilars as more drugs become regulated under the Biologics Price Competition and Innovation Act (BPCIA). Get up to speed on what's to come for#biosimilars in the new year from@JDSupra:http://bit.ly/3a6jOv3Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"Biosimilars are going to be here to stay in my opinion, and it's going to be a great opportunity for community oncology" said Tesh Khullar, Senior Vice President and Advisor, Flatiron Health in a recent video. Watch here:https://bit.ly/2tfqW7O
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In 2017,
@RANDCorporation estimated that biosimilars could save the healthcare system up to $150B from 2017 - 2027. Read the full report on the potential cost-saving benefits of biosimilars.https://bit.ly/372UnZdHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@OubreKathy, COO of Pontchartrain Cancer Center called on payers to reject attempts to block biosimilar access and allow physicians to "prescribe as they know best." Doing so, she argues, will allow#biosimilars to fight financial toxicity. More: http://bit.ly/2Fpxmnd pic.twitter.com/t54z6s2lY3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Read up on the top-five developments in the biosimilars industry last year from
@JDSupra:http://bit.ly/2s3Z8mbHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Julie R. Gralow, Clinical Director, Breast Medical Oncology at
@SeattleCCA and Professor of Medical Oncology at@UW School of Medicine, discussed#biosimilars role for breast cancer in a recent interview with@OncLive.http://bit.ly/37EQ6LFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Read up on the biggest legal developments for U.S.
#biosimilars in 2019 from@BiosimCenter:http://bit.ly/2Qfk6rkHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.